BioSpace News Archive

Elevation Oncology, Inc. announced that Shawn M. Leland, PharmD, RPh, Elevation Oncology’s Founder and Chief Executive Officer, will participate in a pre-recorded fireside chat at the H.C. Wainwright BIOCONNECT Virtual Conference.

Otsuka and Lundbeck Announce FDA Approval of Supplemental New Drug Application for REXULTI ® (brexpiprazole) to Treat Schizophrenia in Pediatric Patients Ages 13-17.

Bluestar Genomics, Inc. today announced that management will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 12 at 4:30 p.m. ET.

Melinta Therapeutics announced today that President and Chief Executive Officer Christine Ann Miller has been elected to the Board of Directors of IVERIC bio, Inc.

Vaxcyte, Inc. (Nasdaq: PCVX), announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for VAX-24, its lead, 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease.

Ampio Pharmaceuticals, Inc., a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, announced that it will present at the H.C. Wainwright Bioconnect Conference occurring virtually on January 10-13, 2022.

Infinity Pharmaceuticals, Inc. today announced that Adelene Perkins, Chief Executive Officer, will give a corporate presentation at 7:30am ET on January 13, 2022 at the 40th annual J.P. Morgan Healthcare Conference, taking place virtually.

Surgalign Holdings, Inc. announced that it has granted restricted stock unit awards to twelve employees, none of whom are executive officers, as an inducement for them to accept employment with Surgalign, and representing the right to receive, in the aggregate, up to 339,241 shares of Surgalign common stock.

Praveen Tyle, Ph.D., Invectys Inc. President and CEO will provide an outlook for the business and its pipeline of treatments for cancer diseases and present an overview of all of Invectys’ projects to date on January 10th.

Marrone Bio Innovations, Inc. has expanded its existing inventory line of credit to support the company’s expectations for growth in sales and manufacturing capacity.